$全球血液疗法(GBT)$ Don’t like the deal. 2M may seem to be a minute number, but what is the rationale behind it? It would appear that the management is concerned about VOC endpoint and want to explore the possibility of combined therapy, or simply an insurance policy. Either way, inclacumab is probably 3-4 years away from approval...